EC Approves Teva's Generic Version Of Neupogen
In a still relatively rare approval of a biosimilar drug, Israeli generic-drug maker Teva Pharmaceutical Industries Ltd. announced Tuesday that the European Commission had approved a copycat version of Amgen Inc.'s...To view the full article, register now.
Already a subscriber? Click here to view full article